Not applicableEnded earlyNCT05068726What this trial is testingClinical Utility of FES F18 PET/CT in Metastatic Breast Cancer PatientsWho this might be right forMetastatic Breast Cancer GE Healthcare 51
Testing effectiveness (Phase 2)UnknownNCT04669587What this trial is testingER+/HER2- Locally Advanced or Metastatic Breast Cancer (ENZENO Study)Who this might be right forEstrogen Receptor-PositiveHER2-NegativeLocally Advanced Breast Cancer+1 more EnhancedBio USA Inc. 106
Testing effectiveness (Phase 2)Ended earlyNCT02202746What this trial is testingAssess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast CancerWho this might be right forBreast CancerMetastatic Breast CancerMBC+5 more Clovis Oncology, Inc. 178
Testing effectiveness (Phase 2)Ended earlyNCT04675827What this trial is testingDe-escalation Adjuvant Chemo in HER2+/ER-/node-neg Early BC Patients Who Achieved PCR After Neoadjuvant Chemo & Dual HER2 BlockadeWho this might be right forHER2-positive Breast CancerER-Negative Breast CancerPR-Negative Breast Cancer+1 more Jules Bordet Institute 139
Early research (Phase 1)Ended earlyNCT05489679What this trial is testingAC682 In Chinese Patients With ER+/HER2- Locally Advanced or Metastatic Breast CancerWho this might be right forBreast Cancer Accutar Biotechnology Inc 6
Large-scale testing (Phase 3)Active Not RecruitingNCT06065748What this trial is testingEvaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)Who this might be right forEstrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Hoffmann-La Roche 1,050
Not applicableStudy completedNCT01928186What this trial is testingFLT PET in Measuring Treatment Response in Patients With Newly Diagnosed Estrogen Receptor-Positive, HER2-Negative Stage I-III Breast CancerWho this might be right forEstrogen Receptor PositiveHER2/Neu NegativeMale Breast Carcinoma+7 more University of Washington 28
Testing effectiveness (Phase 2)WithdrawnNCT01658176What this trial is testingStudy Of PF-04691502 (PI3K/mTOR Inhibitor) In Combination With Exemestane Compared With Exemestane Alone In Patients With Advanced Breast CancerWho this might be right forBreast Neoplasms Pfizer
Testing effectiveness (Phase 2)Ended earlyNCT01430585What this trial is testingPre-Operative Study of PF-4691502 With Letrozole Compared To Letrozole Alone In Patients With Early Breast CancerWho this might be right forEarly Breast Cancer (Phase 2)Advanced Breast Cancer (Phase 1b) Pfizer 14
Not applicableStudy completedNCT02773004What this trial is testingProspective Study Assessing EndoPredict® Genomic Test Impact on Shared Decision of Adjuvant Chemotherapy in Patients With ER-positive, Her2-negative Early Breast CancerWho this might be right forBreast Cancer UNICANCER 203
Large-scale testing (Phase 3)Looking for participantsNCT05901428What this trial is testingTCb vs EC-T in High Risk ER+/HER2- Breast CancerWho this might be right forHormone Receptor Positive HER-2 Negative Breast Cancer Fudan University 1,736
Testing effectiveness (Phase 2)Study completedNCT01105312What this trial is testingPanobinostat and Letrozole in Treating Patients With Metastatic Breast CancerWho this might be right forBreast Cancer Alliance for Clinical Trials in Oncology 28
Large-scale testing (Phase 3)Study completedNCT04629846What this trial is testingStudy in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive and Estrogen Receptor/Progesterone Receptor Negative Breast Cancer to Evaluate the Efficiency and Safety of Treatment With Trastuzumab Plus (+) QL1209/Pertuzumab + Docetaxel.Who this might be right forBreast Cancer Qilu Pharmaceutical Co., Ltd. 517
Testing effectiveness (Phase 2)Study completedNCT02971761What this trial is testingPembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast CancerWho this might be right forAndrogen Receptor PositiveEstrogen Receptor NegativeHER2/Neu Negative+3 more City of Hope Medical Center 18
Early research (Phase 1)Ended earlyNCT01149356What this trial is testingRO4929097 And Exemestane in Treating Pre- and Postmenopausal Patients With Advanced or Metastatic Breast CancerWho this might be right forEstrogen Receptor PositiveHER2/Neu NegativeMale Breast Carcinoma+4 more National Cancer Institute (NCI) 15
Testing effectiveness (Phase 2)Active Not RecruitingNCT04053322What this trial is testingDurvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients.Who this might be right forER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancera Germline or Somatic BRCA Mutation, or a Deleterious Alteration of Other Genes Involved in Homologous Recombination Repair (HRR) or in MSI Status UNICANCER 172
Testing effectiveness (Phase 2)Ended earlyNCT03070002What this trial is testingDenosumab in Treating Patients With ER and/or PR Positive, HER2 Negative Metastatic Breast Cancer With Bone Metastases and Detectable Circulating Tumor CellsWho this might be right forBreast Carcinoma Metastatic in the BoneCirculating Tumor Cell CountEstrogen Receptor Positive+3 more Northwestern University 1
Early research (Phase 1)Looking for participantsNCT05187832What this trial is testingAND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast CancerWho this might be right forAdvanced or Metastatic Breast Cancer Kind Pharmaceuticals LLC 61
Large-scale testing (Phase 3)Active Not RecruitingNCT04546009What this trial is testingA Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)Who this might be right forEstrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer Hoffmann-La Roche 992
Early research (Phase 1)Active Not RecruitingNCT05654532What this trial is testingStudy of AC699 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast CancerWho this might be right forBreast Cancer Accutar Biotechnology Inc 100